CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Beam Therapeutics Inc   (BEAM)
Other Ticker:  
 
 

BEAM's Revenue Growth by Quarter and Year

Beam Therapeutics Inc 's Revenue results by quarter and year




BEAM Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 20.04 51.07 0.01
III Quarter September - 15.80 0.76 0.01
II Quarter June 20.12 16.65 0.01 0.01
I Quarter March 24.21 8.43 0.01 0.01
FY   44.33 60.92 51.85 0.04



BEAM Revenue second quarter 2023 Y/Y Growth Comment
Beam Therapeutics Inc reported Revenue improvement of 20.82% year on year in the second quarter 2023, to $ 20.12 millions, this is lower than Beam Therapeutics Inc 's recent average Revenue surge of 24211.3%.

Looking into second quarter 2023 results within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Revenue growth. While Beam Therapeutics Inc ' s Revenue rise of 20.82% ranks overall at the positon no. 321 in the second quarter 2023.


BEAM Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December - -60.76 % 510600 % -88.89 %
III Quarter September - 1978.95 % 7500 % -100 %
II Quarter June 20.82 % 166400 % 0 % -100 %
I Quarter March 187.19 % 84200 % 0 % -100 %
FY   - 17.49 % 129525 % -100 %

Financial Statements
Beam Therapeutics Inc 's second quarter 2023 Revenue $ 20.12 millions BEAM's Income Statement
Beam Therapeutics Inc 's second quarter 2022 Revenue $ 16.65 millions Quarterly BEAM's Income Statement
New: More BEAM's historic Revenue Growth >>


BEAM Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December - 26.84 % 6619.74 % 0 %
III Quarter September - -5.11 % 7500 % 0 %
II Quarter June -16.91 % 97.51 % 0 % 0 %
I Quarter March 20.81 % -83.49 % 0 % -88.89 %
FY (Year on Year)   - 17.49 % 129525 % -100 %


Explore BEAM Customer Growth by Product and Service >> Back to BEAM Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #68
Overall #321

Revenue Y/Y Growth Statistics
High Average Low
320383.33 % 24211.3 % -100 %
(Jun 30 2022)   (Dec 31 2020)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #68
Overall #321
Revenue Y/Y Growth Statistics
High Average Low
320383.33 % 24211.3 % -100 %
(Jun 30 2022)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Beam Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
12616.67 % 522.03 % -83.49 %
(Sep 30 2021)  


BEAM's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Beam Therapeutics Inc reported fall in Revenue sequentially by -16.91% to $ 20.12 millions, from $ 24.21 millions achived in the previous quarter.

Even cyclical influence that usually fuel II. Quarter 2023 Revenue, have not recover the II. Quarter for the Beam Therapeutics Inc , Marissa D. Johnson, Healthcare sector consultant based in Liverpool wrote, she voiced certan skepticism towards Beam Therapeutics Inc 's outlook, she identified further challenges down the road for Beam Therapeutics Inc .

Within Biotechnology & Pharmaceuticals industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Beam Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1736.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #31
Healthcare Sector #228
Overall #1736
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #31
Healthcare Sector #228
Overall #1736
Revenue Q/Q Growth Statistics
High Average Low
12616.67 % 522.03 % -83.49 %
(Sep 30 2021)  


BEAM's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Beam Therapeutics Inc disclosed fall in Revenue from the previous quarter by -16.91% to $ 20.12 millions, from $ 24.21 millions achived a quarter before.

Although seasonal influence which normally elevate II. Quarter 2023 performance, this simply has not been enough to recover Biotechnology & Pharmaceuticals's company II. Quarter achievement, Marissa D. Johnson, Healthcare sector consultant based in Liverpool said and mentioned that average quarter on quarter Revenue growth is at 522.03% for BEAM.

Within Biotechnology & Pharmaceuticals industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Beam Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1736.


Beam Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 80.16 $ 76.70 $ 60.92 $ 91.95 $ 76.92
Y / Y Revenue Growth (TTM) 4.22 % 27.25 % 17.51 % 11673.62 % 320383.33 %
Year on Year Revenue Growth Overall Ranking # 2 # 1 # 1 # 3 # 2
Seqeuential Revenue Change (TTM) 4.52 % 25.9 % -33.75 % 19.55 % 27.62 %
Seq. Revenue Growth (TTM) Overall Ranking # 321 # 867 # 6 # 111 # 295

New: More BEAM's historic Revenue Growth >>



Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2023 period, Beam Therapeutics Inc 's cumulative twelve months Revenue were $ 80 millions, company would post below average annual Revenue growth of 27.62% year on year, if the fiscal year would end at Jun 30 2023.
A slow-down in the Beam Therapeutics Inc 's Revenue growth from the 24.21% growth in Mar 31 2023.

Beam Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 2.

Revenue TTM Q/Q Growth Statistics
High Average Low
320383.33 %
24211.3 %
-100 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 7
Healthcare Sector # 0
Overall # 2

Revenue TTM Y/Y Growth Statistics
High Average Low
320383.33 %
24211.3 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 68
S&P 500 # 321
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2023 period, Beam Therapeutics Inc 's cumulative twelve months Revenue were $ 80 millions, company would post below average annual Revenue growth of -100% year on year, if the fiscal year would end at Jun 30 2023.
A slow-down in the Beam Therapeutics Inc 's Revenue growth from the 24.21% growth in Mar 31 2023.

Beam Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 2.

Revenue TTM Q/Q Growth Statistics
High Average Low
320383.33 %
24211.3 %
-100 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 7
Healthcare Sector # 0
Overall # 2

Revenue TTM Y/Y Growth Statistics
High Average Low
320383.33 %
24211.3 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 68
S&P 500 # 321




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BEAM's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for BEAM's Competitors
Revenue Growth for Beam Therapeutics Inc 's Suppliers
Revenue Growth for BEAM's Customers

You may also want to know
BEAM's Annual Growth Rates BEAM's Profitability Ratios BEAM's Asset Turnover Ratio BEAM's Dividend Growth
BEAM's Roe BEAM's Valuation Ratios BEAM's Financial Strength Ratios BEAM's Dividend Payout Ratio
BEAM's Roa BEAM's Inventory Turnover Ratio BEAM's Growth Rates BEAM's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Spero Therapeutics Inc 36.28%$ 36.277 millions
Cytomx Therapeutics Inc 36.11%$ 36.108 millions
Axonics Inc 34.67%$ 34.668 millions
Pacific Biosciences Of California Inc 34.06%$ 34.057 millions
Sight Sciences Inc 34.02%$ 34.018 millions
Evolus Inc 32.78%$ 32.783 millions
Insulet Corporation32.43%$ 32.432 millions
Genedx Holdings Corp 32.04%$ 32.038 millions
Predictive Oncology Inc 31.90%$ 31.895 millions
Natera Inc 31.89%$ 31.889 millions
The Oncology Institute Inc 31.69%$ 31.685 millions
Medpace Holdings Inc 31.22%$ 31.224 millions
Sorrento Therapeutics Inc 31.10%$ 31.097 millions
Electromedical Technologies Inc30.94%$ 30.945 millions
Lumos Pharma Inc 30.77%$ 30.769 millions
Caremax Inc 30.28%$ 30.277 millions
Viemed Healthcare Inc 30.02%$ 30.024 millions
Bionano Genomics Inc 29.87%$ 29.865 millions
Thorne Healthtech Inc 29.69%$ 29.690 millions
Rapid Micro Biosystems Inc 29.59%$ 29.585 millions
Akoya Biosciences Inc 29.18%$ 29.183 millions
Ptc Therapeutics inc 29.17%$ 29.169 millions
Apyx Medical Corporation29.02%$ 29.023 millions
Si bone inc 28.93%$ 28.931 millions
10x Genomics Inc 28.71%$ 28.714 millions
Zymeworks Inc 28.67%$ 28.666 millions
Inari Medical Inc 28.32%$ 28.316 millions
Eli Lilly And Company28.11%$ 28.115 millions
United Therapeutics Corporation27.76%$ 27.758 millions
Xtant Medical Holdings Inc 27.37%$ 27.374 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com